Document is current
Any future updates will be listed below
-
Authors
Wojewodzic, Marcin W.
Volders, Ellen L.D.
Meijer, Coby
Grotmol, Tom
Touw, Daan J.
Lubberts, Sjoukje
Haugen, Trine B.
Gietema, Jourik A.
Rounge, Trine B.
-
Funding
Funding for this research was provided by:
Norwegian Institute of Public Health
- License Information
-
More Information
Article History
Received: 2 January 2025
Accepted: 3 October 2025
First Online: 11 November 2025
Declarations
:
: All methods were performed in accordance with the relevant guidelines and regulations. All participants have given informed consent. Participants were part of a prospective study on cardiovascular disease risk during the first year of CBCT treatment in TC patients. This study was performed in the University Medical Centre Groningen (UMCG) between 2008 and 2012 and approved by the Research Ethics Committee of the UMCG. This study was also approved by Regional Ethical Committee (REC) south east D in Norway, reference 2015/1332.
: JG received research funding from Roche, Abbvie and Siemens, paid to the Institution. The rest of authors declare that they have no competing interests.
